参考文献/References:
[1] Abella V,Scotece M,Conde J,et al. The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases[J].Biomarkers,2015,20(8):565-571.DOI:10.3109/1354750X.2015.1123354.
[2] Xiao X,Yeoh BS,Vijay-Kumar M. Lipocalin 2:an emerging player in iron homeostasis and inflammation[J].Annu Rev Nutr,2017,37:103-130. DOI:10.1146/annurev-nutr-071816-064559.
[3] Wang Y,Lam KS,Kraegen EW,et al.Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans[J].Clin Chem,2007,53(1):34-41.DOI:10.1373/clinchem.2006.075614
[4] Catalán V,Gómez-Ambrosi J,Rodríguez A,et al.Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans[J].J Mol Med(Berl),2009,87(8):803-813.DOI:10.1007/s00109-009-0486-8.
[5] Luo Y,Ma X,Pan X,et al.Serum lipocalin-2 levels are positively associated with not only total body fat but also visceral fat area in Chinese men[J]. Medicine(Baltimore), 2016,95(30):e4039. DOI:10.1097/MD.0000000000004039.
[6] Zhao P,Elks CM,Stephens JM.et al.The induction of lipocalin-2 protein expression in vivo and in vitro[J].J Biol Chem,2014,289(9):5960-5969.DOI:10.1074/jbc.M113.532234.
[7] Glaros T,Fu Y,Xing J,et al.Molecular mechanism underlying persistent induction of LCN2 by lipopolysaccharide in kidney fibroblasts[J].PLoS One,2012,7(4):e34633.DOI:10.1371/journal.pone.0034633.
[8] Zhang J,Wu Y,Zhang Y,et al.The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages[J].Mol Endocrinol,2008,22(6):1416-1426. DOI:10.1210/me.2007-0420.
[9] Zhang Y,Guo H,Deis JA,et al.Lipocalin 2 regulates brown fat activation via a nonadrenergic activation mechanism[J].J Biol Chem,2014,289(32):22063-22077.DOI:10.1074/jbc.M114.559104.
[10] Mosialou I,Shikhel S,Liu JM,et al.MC4R-dependent suppression of appetite by bone-derived lipocalin 2[J].Nature,2017,543(7645):385-390.DOI:10.1038/nature21697.
[11] Xiang Y,Zhou P,Li X,et al.Heterogeneity of altered cytokine levels across the clinical spectrum of diabetes in China[J].Diabetes Care,2011,34(7):1639-1641.DOI:10.2337/dc11-0039.
[12] Moreno-Navarrete JM,Manco M,Ibán～ez J,et al.Metabolic endotoxemia and saturated fat contribute to circulating NGAL concentrations in subjects with insulin resistance[J].Int J Obes(Lond),2010,34(2):240-249.DOI:10.1038/ijo.2009.242.
[13] De la Chesnaye E, Manuel-Apolinar L, Zarate A,et al. Lipocalin-2 plasmatic levels are reduced in patients with long-term type 2 diabetes mellitus[J].Int J Clin Exp Med,2015,8(2):2853-2859.
[14] Guo H,Jin D,Zhang Y,et al.Lipocalin-2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice[J].Diabetes,2010,59(6):1376-1385. DOI:10.2337/db09-1735.
[15] Jun LS,Siddall CP,Rosen ED.A minor role for lipocalin 2 in high-fat diet-induced glucose intolerance[J].Am J Physiol Endocrinol Metab,2011,301(5):E825-E835. DOI:10.1152/ajpendo.00147.2011.
[16] Zhang Y,Foncea R,Deis JA,et al.Lipocalin 2 expression and secretion is highly regulated by metabolic stress, cytokines, and nutrients in adipocytes[J]. PLoS One,2014,9(5):e96997.DOI:10.1371/journal.pone.0096997.
[17] Tan BK,Adya R,Shan X,et al.Ex vivo and in vivo regulation of lipocalin-2, a novel adipokine, by insulin[J]. Diabetes Care,2009,32(1):129-131. DOI:10.2337/dc08-1236.
[18] Law IK,Xu A,Lam KS,et al.Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity[J].Diabetes,2010,59(4):872-882.DOI:10.2337/db09-1541.
[19] Wang Y,Lam KS,Kraegen EW,et al.Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans[J].Clin Chem,2007,53(1):34-41. DOI:10.1373/clinchem.2006.075614.
[20] Ye D,Yang K,Zang S,et al.Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2[J].J Hepatol,2016,65(5):988-997.DOI:10.1016/j.jhep.2016.05.041.
[21] Cai Y,Jogasuria A,Yin H,et al.The detrimental role played by lipocalin-2 in alcoholic fatty liver in mice[J].Am J Pathol,2016,186(9):2417-2428.DOI:10.1016/j.ajpath.2016.05.006.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(06):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(06):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(06):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(06):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(06):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(06):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(06):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(06):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]